2026 Market SizeUSD 854.1 MnBase year
2027 EstimateUSD 890.4 MnEstimated year
2036 ForecastUSD 1,290.0 MnForecast value
CAGR4.2%2027–2036
Largest RegionMiddle East & Africa2026
Malaria Rapid Diagnostic Tests (RDTs) Market Overview
The global malaria rapid diagnostic tests market is modeled at USD 854.1 million in 2026, estimated at USD 890.4 million in 2027 and forecast to reach USD 1.3 billion by 2036, representing 4.2% CAGR over 2027–2036.
282 millionEstimated malaria cases worldwide in 2024WHO World Malaria Report 2025
295 millionAt least malaria RDTs sold by manufacturers in 2024WHO World Malaria Report 2025
94%Share of malaria cases in WHO African Region in 2024WHO GHO
2026WHO prequalified additional pLDH and dual-antigen malaria RDTsWHO Prequalification
This market measures revenue from antigen-based, point-of-care malaria rapid diagnostic test kits used to detect Plasmodium infection in whole blood. It excludes malaria microscopy, molecular amplification assays, treatment medicines and unrelated fever diagnostics. Revenue is attributed to the test manufacturer rather than the full clinical visit. WHO recommends parasite-based confirmation before antimalarial treatment, particularly where laboratory microscopy is inaccessible. Accordingly, procurement by national malaria programmes and international donors shapes demand, price and product qualification.
WHO estimated 282 million malaria cases and 610,000 deaths in 2024. The African Region represented about 94% of cases, making sub-Saharan procurement programmes central to test volume. The World Malaria Report 2025 states that manufacturers sold at least 295 million RDTs in 2024, indicating a large existing distribution base. Annual manufacturer revenue, however, is not identical to the value of public procurement orders: freight, intermediary margins, programme expenses and testing services may be counted differently.
Antigen selection is shifting as WHO prequalification expands pLDH-based options for deletion-affected countries. HRP2-based tests are sensitive for typical P. falciparum infections but can miss parasites carrying pfhrp2/3 deletions. WHO advises shifting from exclusive HRP2 detection when deletion-related false negatives reach the relevant threshold. The April 2026 prequalification of BIOCREDIT pLDH alternatives and November 2026 prequalification of two STANDARD Q products expand options for national tender design. Multi-antigen formats can raise specification complexity, but selection must follow field performance and WHO quality criteria.
The forecast uses publisher-reported historical endpoints of USD 786 million in 2024, USD 825 million in 2025 and USD 1,096 million in 2032, normalized to the 2026/2027/2036 framework. It is an analytical projection, not a disclosed worldwide manufacturer-sales census. Donor financing pressure, local manufacturing investments, product prequalification and the changing species mix are principal uncertainties. Procurement prices may decline even as test counts rise, so revenue growth should not be read as proportional growth in the number of tests administered.
Source: WHO World Malaria Report 2025; WHO malaria GHO; WHO BIOCREDIT prequalification; WHO STANDARD Q prequalification.
Key Takeaways: Malaria Rapid Diagnostic Tests (RDTs) Market
- Base-year size: The publisher-normalized 2026 market estimate is USD 854.1 million for antigen-based malaria RDT products.
- Forecast: The 2036 opportunity is projected near USD 1.3 billion, with 4.2% CAGR for 2027–2036.
- Leading type: HRP2-based formats remain important for P. falciparum testing, while pLDH and combination tests gain relevance where gene deletions occur.
- Leading application: Routine diagnosis of symptomatic suspected malaria cases drives recurring test demand across endemic health systems.
- Largest region: Africa is the leading demand region, reflecting the WHO African Region’s disproportionate malaria burden.
- Drivers: Expanded community testing, WHO prequalification and the need to avoid empiric antimalarial treatment support demand.
- Risks: Donor budget constraints, tender price compression and pfhrp2/3 deletions create uncertainty in the product mix.
- Coverage: The study analyzes four segmentation dimensions, five geographic regions, manufacturers, procurement and technology developments.
Report Scope & Market Segmentation
Manufacturer-level sales of malaria antigen rapid diagnostic tests for clinical and community point-of-care testing, excluding molecular and microscopy-based methods.
| Report Attribute | Coverage |
|---|
| Base Year | 2026 |
| Estimated Year | 2027 |
| Forecast Period | 2027–2036 |
| Market Measurement | Revenue, USD million/billion |
| By Antigen | HRP2-only; pLDH-only; HRP2/pLDH Combination; Other Antigen Combinations |
| By Parasite Detection | P. falciparum Only; P. vivax Only; Multi-species |
| By End User | Public Health Programmes; Hospitals and Clinics; Community Health Workers; Private Laboratories |
| By Procurement Channel | National Government Tenders; International Donor Procurement; Private Distribution; Humanitarian and Emergency Procurement |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | Nigeria; Democratic Republic of the Congo; Uganda; Ethiopia; India; Indonesia; Brazil; Peru; United States |
| Key Market Players | Abbott Rapid Dx International; SD Biosensor; Rapigen; Premier Medical Corporation; Advy Chemical; Arkay Healthcare; Meril Diagnostics |
Market Definition & Revenue Boundaries
In-scope products are disposable immunochromatographic malaria RDT kits that detect parasite antigens in a patient blood sample. The market includes single-species and multi-species formats sold to governments, donors, health facilities and distributors. It excludes microscopes, PCR reagents, therapeutic drugs, laboratory service fees and unrelated rapid tests. Geographic revenue allocation follows estimated destination demand rather than the location of the manufacturer.
The Antigen dimension groups tests by detection target, while Parasite Detection groups by species coverage; these are separate analytical dimensions and must not be summed together. End User describes where tests are administered, and Procurement Channel describes who purchases or finances them. Product selection depends on WHO prequalification, field stability, antigen-deletion surveillance and local species epidemiology.
Malaria Rapid Diagnostic Tests (RDTs) Market Dynamics
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Endemic disease burden and community testing expansion | High | +2.10% | High | High | Medium |
| WHO prequalification of additional antigen formats | Medium | +1.40% | High | Medium | Medium |
| Expanded public-sector screening and surveillance | Medium | +1.20% | Medium | High | High |
| Supply chain improvements and local distribution | Low | +0.50% | Medium | Medium | High |
| Others (emergency stocks and outreach programmes) | Low | +0.30% | Low | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2027–2029 | 2030–2032 | 2033–2036 |
|---|
| Donor funding volatility and tender delays | High | -0.70% | High | High | Medium |
| Competitive tender price pressure | Medium | -0.40% | Medium | High | High |
| Others (product switching and compliance costs) | Low | -0.20% | Medium | Medium | Low |
*CAGR contribution shows the percentage points each factor adds to or removes from the 4.2% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
High endemic disease burden sustains testing demand
WHO estimated 282 million malaria cases in 2024, including 94% in its African Region. This burden creates a large recurring need to distinguish malaria from other febrile illnesses before treatment. National programmes purchase rapid tests for clinics and community workers because microscopy is unavailable in many remote areas. The scale of demand depends on suspected fever presentations, testing protocols, supply continuity and funding, not just confirmed infections. Donor procurement and local budget decisions therefore influence manufacturer sales.
Prequalification and alternative antigens support product replacement
WHO prequalified three BIOCREDIT malaria assays in April 2026 and two STANDARD Q assays in November 2026. The newer tests broaden choices for P. falciparum and P. vivax detection, including alternatives that incorporate pLDH antigens. This matters where parasites have deleted pfhrp2 or pfhrp3 genes and exclusive HRP2-based assays can miss infections. Replacement programmes may generate orders for different test configurations, although procurement agencies still assess stability, quality, performance and delivered price. Country-specific field validation should assess sensitivity against local parasite strains before widespread procurement.
Procurement funding gaps constrain volume and realized revenue
The Global Fund pools purchasing to obtain competitive prices for diagnostic tests and other health products. UNICEF also supplies malaria RDTs to remote communities. International tender pricing can compress unit revenues even where the number of tests increases. Interruptions in grant disbursement or national budget allocations can delay orders, increase stock-out risks and reduce access to diagnosis. Suppliers must balance affordability with manufacturing quality and reliable delivery, making revenue growth sensitive to funding and procurement cycles.
Genetic deletions complicate selection and clinical sensitivity
WHO guidance notes that pfhrp2/3 deletions may produce false-negative HRP2 rapid-test results. Its response plan recommends surveillance and switching away from exclusive HRP2 assays when the relevant threshold of deletion-related false negatives is reached. This changes procurement specifications and increases the value of alternative antigen detection, but the transition is not uniform across countries. Local parasite epidemiology, quality-control systems and training determine which format is appropriate and how quickly procurement contracts change. Surveillance of pfhrp2/3 deletions supports evidence-based decisions on replacement of HRP2-only tests.
Local manufacturing and logistics reshape tender competition
UNICEF procurement documentation identifies a historical mix of manufacturers in India and South Korea, while more recent initiatives seek to expand African diagnostic manufacturing. Local assembly or production can shorten replenishment lead times and support regional resilience, but it must still meet stringent quality standards. Malaria RDTs require suitable shelf life, temperature tolerance and reliable performance during field distribution. Competitive advantage therefore combines manufacturing scale, prequalification, distribution capacity and tender responsiveness rather than test chemistry alone.
Sources: WHO World Malaria Report 2025; WHO prequalification notices; UNICEF malaria rapid diagnostics bulletin; The Global Fund procurement tools.
Market Trends & Growth Opportunities
Alternative pLDH formats gain procurement attention
The emergence of pfhrp2/3 gene deletions is changing malaria diagnostic procurement in affected countries. WHO guidance advises using evidence from surveillance before switching from exclusive HRP2 tests to pLDH-containing alternatives. WHO prequalification decisions in 2026 expanded the available product range, allowing national programmes to compare formats based on local parasite biology. The transition will remain geographically uneven because deletion prevalence and laboratory infrastructure differ by country. Manufacturers able to document performance under relevant conditions may gain tender opportunities.
Combination tests support species-specific case management
Some malaria rapid tests detect only P. falciparum, while others differentiate P. falciparum and P. vivax or identify multiple species. WHO describes the importance of matching target antigens and parasite coverage to local epidemiology. Combination formats can improve the clinical information available to frontline workers without requiring microscopy. However, product choice also depends on cost, shelf stability and practical ease of use. Buyers must evaluate actual diagnostic performance rather than assume that additional antigen lines always deliver better field outcomes.
Community-level testing remains a public health priority
WHO recommends parasite-based diagnosis before antimalarial treatment, and malaria RDTs enable confirmation in settings where microscopy is impractical. UNICEF has supplied tests to remote communities for many years, including programmes serving children at high risk of severe disease. Community health worker distribution can expand testing access and reduce presumptive treatment, but only when kits, training and treatment referral pathways remain available. Procurement volumes are therefore closely connected to broader primary-care programme financing and logistical execution.
Procurement increasingly prioritizes quality assurance
WHO recommends prequalified malaria RDTs for routine procurement and publishes product assessments covering performance and manufacturing quality. UNICEF and the Global Fund also operate purchasing mechanisms designed to improve quality and value for money. Tender specifications increasingly reflect antigen suitability, storage conditions and delivered cost, not simply the lowest ex-factory unit price. Manufacturers that sustain documentation, stable supply and robust batch performance are better positioned for long-term contracts, while weaker suppliers face higher qualification barriers.
Regional production efforts aim to reduce import dependence
Malaria RDT supply chains historically rely heavily on manufacturers serving international donor tenders. New regional production efforts could shorten lead times and improve emergency response when global logistics are disrupted. Yet manufacturing location alone does not guarantee access: products still require validated performance, regulatory compliance and a reliable procurement pipeline. The market may gradually diversify geographically, but demand remains concentrated in endemic regions and large public programmes. Price competition and quality oversight will determine the commercial outcome.
Malaria Rapid Diagnostic Tests (RDTs) Market Segmentation by Antigen
Report SegmentationBy Antigen
Malaria RDTs differ by parasite antigen detected. HRP2-based formats remain widely used, while pLDH-based and combination products offer alternatives for settings affected by gene deletions. Selection follows WHO guidance and local surveillance.
Established AntigenHRP2-only
HRP2 assays have been widely used for P. falciparum diagnosis because of their diagnostic performance and ease of use. Their limitation is that parasites lacking the pfhrp2/3 genes can escape detection, requiring programme-level surveillance and alternative test strategies in affected areas. Tender buyers must evaluate local epidemiology before maintaining exclusive HRP2 procurement.
Alternative DetectionpLDH-only
pLDH assays detect parasite lactate dehydrogenase rather than relying solely on HRP2 expression. WHO prequalified BIOCREDIT products in 2026, expanding the options available to buyers addressing gene deletions. Adoption depends on clinical performance, local prevalence and supply readiness, not a universal replacement mandate.
Combination FormatHRP2/pLDH Combination
Dual-antigen tests combine detection pathways and may improve diagnostic flexibility across different parasite populations. New WHO prequalification decisions in 2026 are relevant to tender design, although field performance and test-line interpretation remain essential. Combination formats can also support species differentiation when the assay includes appropriate targets.
Antigen selection is increasingly a country-specific procurement decision informed by deletion surveillance and WHO prequalification. Programme managers should track the prevalence of false-negative results, review independent performance assessments and plan transition stock carefully. More complex test configurations may also require additional training for field workers and quality-control procedures.
Malaria Rapid Diagnostic Tests (RDTs) Market Segmentation by Parasite Detection
Report SegmentationBy Parasite Detection
Products differ by whether they identify P. falciparum, P. vivax or multiple species. This classification reflects the clinical result reported by the kit rather than its antigen chemistry.
Largest Disease FocusP. falciparum Only
P. falciparum causes most malaria deaths globally and remains central to public-health testing programmes in Africa. Single-species tests can provide a practical option where falciparum predominates. However, local genetic deletions may alter the suitability of HRP2-only formats, so species coverage and antigen target must be considered separately.
Regional Species NeedP. vivax Only
P. vivax detection is particularly important in parts of Asia and Latin America, where species identification affects clinical management. Demand is smaller than the global falciparum testing pool but is meaningful for programmes targeting elimination and mixed transmission. Product specifications depend on local parasite distribution and available treatment pathways.
Broad DetectionMulti-species
Multi-species RDTs identify or distinguish more than one Plasmodium species and are useful where falciparum and non-falciparum infections coexist. Their value lies in providing actionable information at the point of care without full laboratory support. WHO guidance calls for assessing test performance, thermal stability and procurement cost before product selection.
Species mix is geographically heterogeneous, making one global assay configuration unsuitable for every programme. Mixed-transmission settings may require combination tests to avoid misclassification, whereas high-burden falciparum programmes may prioritize sensitivity for that species. Diagnostic purchasing must be coordinated with national treatment protocols, supply forecasts and local surveillance data.
Malaria Rapid Diagnostic Tests (RDTs) Market Segmentation by End User
Report SegmentationBy End User
Public malaria programmes, health facilities and community workers administer most tests in endemic settings, while private laboratories and clinics serve supplementary demand.
Programme DemandPublic Health Programmes
National malaria control programmes procure tests for distribution across health facilities and outreach networks. The WHO recommendation for parasite confirmation before treatment supports ongoing demand. Procurement is highly dependent on national budgets, donor financing and consistent inventory management.
Facility TestingHospitals and Clinics
Hospitals and clinics use malaria RDTs for rapid assessment of febrile patients, especially when microscopy is unavailable or delayed. Test results help clinicians choose treatment or investigate alternative causes of fever. Quality assurance and stock management are necessary to maintain reliable use.
Remote AccessCommunity Health Workers
Community workers provide access to parasite-based diagnosis in hard-to-reach populations. UNICEF identifies malaria rapid tests as important to child survival and primary-care delivery. Training, referral pathways and steady test availability determine programme impact.
End-user demand is driven by clinical workflow and programme reach rather than independent retail consumption alone. Hospital workflows emphasize rapid triage and treatment decisions, while community outreach emphasizes portable kits, simple instructions and temperature stability. Procurement agencies need to plan for seasonal surges, staff training and replenishment so expanded test access translates into appropriate care. Public-sector volumes also depend on timely donor disbursement and local budget commitments. These operating requirements create recurring demand for quality-assured suppliers and resilient distribution networks.
Malaria Rapid Diagnostic Tests (RDTs) Market Segmentation by Procurement Channel
Report SegmentationBy Procurement Channel
Malaria RDT purchasing spans national tenders, donor-supported procurement, private distribution and humanitarian response. WHO prequalification and delivered tender pricing influence how different buyers select rapid-test products.
Institutional BuyersNational Government Tenders
National malaria programmes purchase large volumes under competitive tenders. Selection criteria typically include prequalification, local species coverage, shelf stability, delivery schedules and price. National tender schedules and inventory planning determine when programmes place orders for diagnostic kits.
Pooled PurchasingInternational Donor Procurement
The Global Fund pooled procurement mechanism aggregates orders and supports quality-assured product access. UNICEF also purchases malaria diagnostics for high-risk communities. These channels can stabilize demand but exert pressure on manufacturer prices and documentation requirements.
Supplementary ChannelsPrivate Distribution
Private clinics, pharmacies and laboratories buy through distributors where national rules allow. These orders may have different margins and packaging needs than public tenders, but overall demand still follows local malaria incidence and testing guidance.
Procurement diversification can improve supply resilience, although donor financing remains important in high-burden countries. International tenders often establish reference prices and strict product qualification requirements. Domestic procurement may support local manufacturers where regulatory and quality requirements are met, while humanitarian orders can surge during outbreaks or displacement. Buyers should account for freight, temperature stability, remaining shelf life, training and quality assurance alongside nominal unit price. The mix of channels therefore changes manufacturer revenue realization even if total test demand remains stable.
Malaria Rapid Diagnostic Tests (RDTs) Market Regional Analysis
Regional demand for malaria RDTs reflects the burden of suspected malaria, national diagnostic policies, donor financing, parasite species and availability of microscopy. Africa leads in volume; Asia-Pacific and Latin America require different antigen and species configurations. North America and Europe mainly serve imported-case diagnosis and manufacturer supply chains.
North America
Imported-case testing - Smaller clinical demandNorth America has comparatively limited locally acquired malaria transmission, so routine RDT demand is concentrated in imported-case evaluation, travel medicine and selected emergency care settings. Microscopy and molecular methods remain important in hospital diagnosis, limiting the size of the rapid-test opportunity. Public health agencies emphasize accurate case identification and timely treatment for patients returning from endemic countries. Regional companies also contribute to diagnostic technology development, regulatory review and global supply. Procurement priorities differ from those in high-burden African settings: hospitals typically seek reliable differential diagnosis and integration with existing laboratory pathways rather than mass community distribution. The regional market therefore depends more on travel patterns, clinical testing protocols and product availability than on large malaria-control tenders. It is important not to infer the geographic location of demand from the headquarters of a multinational test supplier. Consistent clinical guidelines and access to confirmatory laboratories are important safeguards for imported cases, especially when symptoms are nonspecific.
Priority country signals
United States
Selected market signalImported malaria is evaluated through clinical laboratories and hospital services, with RDTs serving as a potential adjunct to established testing. Confirmatory methods and clinician awareness remain important because a negative rapid test cannot always exclude malaria. US clinical demand largely concerns imported malaria cases rather than endemic community-wide distribution. Severe suspected malaria cases require prompt clinical assessment and access to confirmatory laboratory methods.
Source: WHO.
Europe
Imported-case diagnostics - Laboratory-led careEurope is not a major endemic malaria market, and WHO reports that its European Region has been free of indigenous malaria transmission since 2015. Demand therefore arises mainly from travellers, migrants and imported-case clinical assessment. Hospitals and specialist infectious-disease laboratories retain a prominent role, and malaria RDTs complement microscopy and other confirmatory testing. Manufacturers and distributors in Europe participate in global diagnostic supply chains, but those sales should be attributed to the final destination of the test rather than the manufacturer location. Regulatory compliance, assay reliability and clinician training are more prominent commercial factors than very large public-health malaria tenders. The market remains smaller than endemic-region demand and may fluctuate with travel activity and imported disease patterns. Strong laboratory networks and surveillance help prevent delays in diagnosing severe imported infections and support appropriate use of rapid assays. Public procurement typically covers hospital diagnostics rather than the broad community screening networks used in sub-Saharan Africa. Clinical pathways should account for test limitations, including false-negative results and the need for follow-up testing. Clinical testing requires documented kit performance and appropriate confirmation when suspicion remains high. Clinicians must also consider travel history, species identification and the urgency of treatment when malaria is suspected.
Priority country signals
United Kingdom
Selected market signalMalaria evaluation is largely associated with imported infection and specialist clinical care. Rapid tests may support initial assessment where appropriate, but confirmatory testing and access to expert laboratories remain central. Demand is shaped by travel and case referrals rather than mass local transmission. Hospital procurement therefore emphasizes documented performance and suitable specimen-handling workflows.
Source: WHO.
Asia-Pacific
Species-diverse demand - Elimination and controlAsia-Pacific includes settings with P. vivax and P. falciparum transmission, making species discrimination an important feature of diagnostic procurement. India and several Southeast Asian countries operate malaria control and elimination programmes that require tests suited to local epidemiology. In remote communities, RDTs can extend parasite confirmation where microscopy is difficult to sustain. Procurement also reflects the varying availability of public funding, donor support and domestic manufacturing capacity. As transmission declines in some districts, programmes may shift from high-volume fever testing toward targeted surveillance and rapid response, changing the preferred pack sizes and distribution model. Mixed-species formats remain useful where different parasites coexist, while tests selected for falciparum-dominant areas must account for local deletion surveillance. The region is also home to established diagnostic manufacturers serving international tenders. Geographic market sizing should distinguish local consumption from exports produced in the region. Quality assurance and antigen selection become increasingly important as countries progress toward elimination and focus on detecting residual transmission.
Priority country signals
India
Selected market signalIndia combines domestic diagnostic manufacturing with a national malaria elimination agenda. Procurement must address diverse parasite epidemiology and differences between urban and remote health facilities. Field suitability, quality assurance and consistent access to confirmatory diagnosis are important factors. Local health authorities also need to plan training, distribution and follow-up pathways for positive and negative rapid-test results.
Source: WHO.
Latin America
Deletion-sensitive procurement - Targeted surveillanceLatin American malaria programmes serve heterogeneous transmission zones, including remote forest and border communities where laboratory infrastructure is constrained. P. vivax remains relevant in several countries, and species-specific treatment decisions make differentiated rapid-test results valuable. WHO has documented pfhrp2/3 deletions in parts of the region, prompting attention to alternatives to exclusive HRP2 detection. The need for local validation can increase procurement complexity and change the mix of test formats purchased. Country programmes balance routine testing, outbreak response and elimination surveillance, with volumes dependent on incidence and public financing. Distribution into remote locations raises the importance of shelf stability and supply-chain planning. The market is smaller than Africa in absolute test volume but can be important for alternative antigen product adoption. Regional procurement should not treat all Latin American countries as having the same parasite species mix or gene-deletion prevalence.
Priority country signals
Brazil
Selected market signalBrazil has documented malaria transmission and pfhrp2/3 deletion concerns in affected areas. Product selection must follow local surveillance, including whether exclusive HRP2 tests remain suitable. Remote Amazonian distribution and local P. vivax transmission shape the need for suitable species-differentiating assays. Procurement programmes should account for heat exposure during distribution and confirmatory testing where clinical suspicion remains high.
Source: WHO.
Peru
Selected market signalPeru was among the first locations where pfhrp2 deletions raised concerns about HRP2-based diagnosis. Alternative antigen selection and continued surveillance remain relevant to procurement, particularly in remote endemic communities. National surveillance can identify when changing antigen targets will improve the reliability of malaria case management. Local validation against circulating parasite strains helps determine whether antigen-target changes are appropriate.
Source: WHO.
Middle East & Africa
Largest demand region - High endemic burdenAfrica is the principal market for malaria rapid diagnostic tests because the WHO African Region accounted for about 94% of global malaria cases and 95% of malaria deaths in 2024. Large national programmes distribute tests to hospitals, clinics and community health workers, frequently supported by donors and pooled procurement. WHO estimates 282 million global malaria cases in 2024, underscoring the recurring need for parasite confirmation. The region also faces important procurement risks from donor financing pressures, supply interruptions and pfhrp2/3 deletions in certain countries. These factors increase demand for reliable antigen alternatives and robust field performance. National procurement decisions differ according to species distribution, deletion prevalence, budget and logistics. Emerging regional manufacturing initiatives may support resilience but still require quality assurance and sustained purchasing commitments. Middle Eastern countries vary widely in endemicity, and imported-case diagnostics should be distinguished from high-volume community testing in African countries. Test demand is driven by the scale of suspected febrile illness, not simply the number of confirmed malaria infections.
Priority country signals
Nigeria
Selected market signalNigeria is among the countries with the greatest malaria burden. Public programmes and donor-supported procurement make rapid diagnosis an important part of fever management. Reliable supply to frontline facilities and quality-assured test selection remain central operational priorities. Distribution networks need to reach rural clinics and community health workers before seasonal peaks in suspected cases.
Source: WHO.
Ethiopia
Selected market signalEthiopia has been affected by pfhrp2/3 deletions, making the choice of antigen targets particularly important. WHO guidance supports surveillance and switching away from exclusive HRP2 tests where the defined threshold is met. New pLDH-containing products may help address these gaps, subject to field performance and procurement qualification. Health workers need training on interpreting new test-line configurations and responding to negative results.
Source: WHO.
Competitive Landscape
Malaria rapid diagnostic tests are supplied through a mix of multinational diagnostic manufacturers, Asian specialist producers and regional manufacturers. WHO prequalification and international tender qualification are important competitive differentiators. Historical UNICEF supplier listings demonstrate breadth of participation, but do not establish current market shares or 2026 tender awards.
WHO-prequalified supplierSD Biosensor
WHO prequalified two STANDARD Q malaria RDT products in November 2026. These products detect combinations of HRP2 and pLDH antigens, with a format supporting differentiation of P. falciparum and P. vivax. The decision adds options for buyers evaluating species coverage and deletion-related risks.
Alternative antigen manufacturerRapigen
WHO announced prequalification of three BIOCREDIT malaria assays in April 2026, including pLDH-based products. This expands the pool of qualified alternatives for procurement programmes facing pfhrp2/3 deletion concerns. Qualification does not itself establish tender volumes or revenue shares.
Established international supplierAbbott Rapid Dx
UNICEF procurement documentation identified Abbott Rapid Dx International as a supplier under historical long-term arrangements. WHO product assessments also document Bioline malaria rapid-test configurations. Ongoing tender participation should be assessed against current contracts and product prequalification records.
Regional and specialist suppliersPremier Medical, Advy Chemical, Arkay Healthcare and Meril Diagnostics
UNICEF historical supply reporting identifies these India-linked suppliers in its malaria RDT procurement arrangements. Their inclusion illustrates competitive breadth, not a claim that all hold active 2026 tenders. Quality assurance, product availability and price are essential to current qualification.
Competition depends on documented field performance, prequalification status, antigen design, manufacturing capacity, temperature stability and delivered tender price. The emergence of pfhrp2/3 deletions may create opportunities for suppliers of alternative antigen products, but replacement decisions remain country-specific and must be supported by surveillance. Manufacturers also need to maintain quality management and responsive distribution to avoid stock interruptions during seasonal peaks.
The Global Fund and UNICEF influence purchasing specifications and supplier economics through pooled procurement and quality-assured sourcing. Historical tender awards cannot be treated as contemporary market shares, particularly when programmes change antigen requirements or financing. New manufacturing projects in endemic countries may alter logistics and competition, but only after products meet appropriate regulatory and performance standards. Donor grant disbursement schedules and national tender calendars determine when diagnostic-kit orders are placed.
Key Companies Profiled
- Abbott Rapid Dx International
- SD Biosensor
- Rapigen
- Premier Medical Corporation
- Advy Chemical
- Arkay Healthcare
- Meril Diagnostics
Recent Developments in the Malaria Rapid Diagnostic Tests (RDTs) Market
November 2026: WHO prequalified the STANDARD Q Malaria P.f Ag Pro Test and STANDARD Q Malaria P.f/P.v Ag Pro Test. The announcement describes HRP2 and pLDH antigen targets for symptomatic patients, broadening the available product configurations. The regulatory milestone is relevant to procurement planning but does not establish sales volumes. Source
April 2026: WHO announced prequalification of three BIOCREDIT malaria tests detecting pLDH antigens, including configurations for P. falciparum and P. vivax. These products provide quality-assured alternatives where HRP2/3 gene deletions undermine exclusive HRP2 testing. National procurement decisions should use pfhrp2/3 surveillance data to assess when new antigen formats are appropriate. Implementation requires verified performance under field conditions and training for workers interpreting new test formats. Source
April 2026: WHO updated several public assessment reports for prequalified in-vitro diagnostics, including Bioline malaria products. The revisions support current labelling and product documentation for procurement teams. Quality-assurance records are an important input to product selection and should be reviewed alongside national diagnostic policies. The updates help buyers compare current specifications before tender awards. Source
December 2025: WHO published its World Malaria Report 2025, estimating 282 million cases and 610,000 deaths in 2024. The report highlighted drug resistance, diagnostic challenges and financing pressures. It also documented the continued importance of malaria rapid tests and surveillance of parasite gene deletions. WHO burden estimates and parasite surveillance findings help national programmes forecast diagnostic procurement needs. Source
December 2024: WHO released the second edition of its response plan to pfhrp2 gene deletions. The plan addresses surveillance, alternative biomarkers and RDT market implications in affected countries. It supports a more evidence-based transition away from exclusive HRP2 testing where local false-negative rates warrant action. The guidance also calls for research and strengthening laboratory networks. Source
November 2024: UNICEF published a technical bulletin on malaria rapid diagnostics available through its procurement channels. It emphasized quality-assured parasite confirmation, particularly for children and remote communities. The guidance reinforces the role of reliable rapid tests when microscopy is unavailable and supports appropriate product specification in public programmes. Source
Market Outlook, 2027–2036
The malaria rapid diagnostic tests market is projected to increase from USD 890.4 million in 2027 to USD 1,290.0 million in 2036, representing a 4.2% CAGR over the 2027–2036 period. The forecast extrapolates the publisher-reported 2024 and 2032 market values using the normalized annual growth rate.
| Forecast Variable | 2026 Baseline | Expected Effect Through 2036 |
|---|
| Malaria burden | 282 million cases in 2024 per WHO | Sustains demand for accessible parasite confirmation |
| Antigen innovation | WHO prequalified pLDH products in 2026 | Changes procurement mix in deletion-affected countries |
| Procurement financing | Global Fund and UNICEF purchasing channels | Determines tender timing and realized unit prices |
| Community testing | RDTs support diagnosis outside laboratories | Extends access in remote endemic settings |
| Local production | Historical supply concentrated in multiple Asian producers | Potentially diversifies supply and shortens lead times |
| Quality assurance | WHO prequalification and performance standards | Supports reliable field deployment and supplier qualification |
The projected revenue trajectory is moderate relative to public-health need. WHO reported at least 295 million malaria RDTs sold by manufacturers in 2024, but procurement revenue depends on the price per kit, product configuration and channel. Donor-financed tenders may generate substantial volumes while applying pressure to manufacturer margins. Public-sector budget uncertainty could delay replacement orders even when fever testing remains medically necessary. The publisher model should therefore be interpreted as a scenario consistent with historical reported endpoints rather than a direct measurement of every global transaction.
Technology mix will likely change as malaria programmes respond to pfhrp2/3 deletions. WHO guidance emphasizes surveillance before moving away from exclusive HRP2 testing. The April and November 2026 prequalification announcements add pLDH and multi-antigen products to the qualified selection pool. Supplier differentiation will depend on quality documentation, field performance, shelf stability and dependable supply.
Geographic demand will continue to be concentrated in high-burden African countries. The WHO African Region represented 94% of global malaria cases in 2024, although the market’s revenue allocation can differ from case shares because procurement prices and channels vary. Asia-Pacific and Latin America have different parasite mixes and elimination priorities, which influence the value of species-differentiating tests. Europe and North America mainly contribute imported-case diagnostic demand and manufacturing or distribution functions, rather than large endemic testing programmes.
The central risks are donor funding cuts, public tender delays, price compression and the operational difficulty of changing diagnostic specifications. Potential upside comes from stronger community-health distribution, reliable replacement of underperforming antigen formats and improved procurement continuity. Manufacturers that combine appropriate prequalification with regional logistics and transparent quality data are better positioned to serve national programmes. Future updates should distinguish test unit volumes, manufacturer net sales and full programme expenditure to avoid conflating these different economic measures.
By 2036, demand is expected to remain closely tied to parasite confirmation policies and local malaria burden rather than discretionary consumer testing. Monitoring WHO surveillance updates, prequalification decisions, UNICEF supply publications and Global Fund procurement records provides the strongest basis for revising the forecast. A transparent model must incorporate local epidemiology, antigen suitability, quality requirements, financing and changes in procurement prices.
Report Coverage
The report evaluates malaria RDT products, manufacturers, procurement pathways and field requirements using the 2026 base / 2027 estimate / 2036 forecast framework.
Market Size & Forecast2026 base-year value, 2027 estimate, 2036 forecast and CAGR for 2027–2036.
Product SegmentationAntigen, parasite detection, end user and procurement channel dimensions.
Regional AnalysisFive regions with endemic burden, imported-case testing and selected country contexts.
Competitive LandscapeWHO-qualified suppliers and historical UNICEF procurement participants, with evidence limits.
Market DynamicsTesting demand, financing, price pressure, quality standards and antigen deletion risks.
Regulatory & Technology DevelopmentsWHO prequalification updates, surveillance protocols and pLDH alternatives.
Frequently Asked Questions
How large is the malaria RDT market?
The publisher-normalized estimate is USD 854.1 million in 2026 and USD 890.4 million in 2027, with a forecast of USD 1,290.0 million in 2036. These values are analytical estimates, not audited worldwide manufacturer sales. The projection extends the publisher’s historical market endpoints rather than independently measuring all diagnostic sales.
What CAGR is forecast for malaria rapid diagnostic tests?
The model projects a 4.2% compound annual growth rate for 2027–2036, using the 2027 and 2036 revenue endpoints. The projection is based on publisher historical endpoints and is sensitive to procurement financing and test prices.
Why are malaria rapid diagnostic tests important?
They support parasite-based confirmation before treatment, particularly where microscopy is not accessible. WHO recommends rapid or microscopy-based diagnosis for suspected malaria. WHO recommends confirmation of suspected malaria before treatment to reduce inappropriate antimalarial use and improve surveillance.
Which region has the greatest demand?
Middle East and Africa leads the modeled market because malaria burden and public procurement are concentrated in Africa. WHO reports that its African Region accounted for 94% of cases in 2024. Procurement values can differ from case shares because prices, product mixes and distribution channels vary across countries.
What do HRP2 and pLDH malaria tests detect?
HRP2 and pLDH are parasite antigen targets used in immunochromatographic tests. pLDH alternatives matter where pfhrp2/3 gene deletions undermine exclusive HRP2 detection. WHO recommends reviewing local gene-deletion surveillance before replacing exclusive HRP2 tests with alternatives.
Which malaria species can RDTs detect?
Depending on the kit, tests may detect P. falciparum, P. vivax or multiple Plasmodium species. WHO guidance recommends matching antigen and species coverage to local parasite epidemiology. WHO prequalification evaluates product quality, while local transmission patterns determine the most suitable species coverage.
Who buys malaria rapid tests?
National malaria programmes, international donors, public health facilities, private distributors and humanitarian organizations are important procurement channels. Large buyers also evaluate quality assurance, product shelf life, antigen coverage and delivery reliability in procurement decisions. WHO advises buyers to select antigen targets using local species prevalence and gene-deletion surveillance.
Which companies supply malaria rapid diagnostic tests?
WHO announcements document prequalified products from SD Biosensor and Rapigen. UNICEF historical procurement materials identify Abbott, Premier Medical and several Indian suppliers. Historical supplier lists do not prove current tender awards or manufacturer revenue shares in 2026.
How do gene deletions affect malaria testing?
Parasites with pfhrp2/3 deletions can produce false-negative HRP2 tests. WHO recommends surveillance and a change in strategy where relevant thresholds are reached. The WHO response plan sets out surveillance approaches and procurement implications for countries affected by these deletions.
What are the principal market restraints?
Donor funding volatility, tender price competition, logistics, quality requirements and changing antigen specifications can limit revenue growth. Product prequalification and transport conditions also influence which suppliers can fulfill large public-sector contracts. Funding reductions can delay national malaria programme orders even when test demand persists.
What is WHO prequalification for malaria RDTs?
WHO prequalification assesses diagnostic product performance, quality and manufacturing systems, supporting procurement decisions by public health programmes. The process includes review of product documentation, laboratory performance and manufacturing quality before qualification. WHO recommends prequalified RDTs for public procurement where appropriate products are available.
What is the market outlook through 2036?
Demand is supported by community testing and endemic disease burden, while financing constraints and procurement prices moderate revenue growth. Alternative antigen formats are likely to become more important in affected countries. WHO prequalification of alternative antigen products in 2026 may change product mix in affected countries.
Research Sources & Evidence Base
View research sources used for this overview